VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH CML 2022 | The role of CML stem cells in relapse after TKI discontinuation & resistance to treatment

Giuseppe Saglio, MD, University of Turin, Turin, Italy, emphasizes the importance of better understanding chronic myeloid leukemia (CML) stem cells in order to prevent treatment resistance and relapse following tyrosine kinase inhibitor (TKI) discontinuation. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter